These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 32233753)

  • 1. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
    Sommerstein R; Kochen MM; Messerli FH; Gräni C
    J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
    Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR
    J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
    Patel AB; Verma A
    JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
    [No Abstract]   [Full Text] [Related]  

  • 5. Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.
    Jennings GL
    Med J Aust; 2020 Jun; 212(11):502-503.e1. PubMed ID: 32441063
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety.
    Akhtar S; Benter IF; Danjuma MI; Doi SAR; Hasan SS; Habib AM
    J Drug Target; 2020; 28(7-8):683-699. PubMed ID: 32700580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
    Brojakowska A; Narula J; Shimony R; Bander J
    J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ACEIs/ARBs in COVID-19: Friend or foe?
    Zhou Z; Qiu Y; Tao J
    Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
    Sinha S; Sehgal A; Sehgal R
    Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
    Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
    N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
    Usman MS; Siddiqi TJ; Khan MS; Ahmed A; Ali SS; Michos ED; Hall ME; Krasuski RA; Greene SJ; Butler J; Alkhouli M
    Am J Cardiol; 2020 Sep; 130():159-161. PubMed ID: 32624189
    [No Abstract]   [Full Text] [Related]  

  • 12. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.
    South AM; Brady TM; Flynn JT
    Hypertension; 2020 Jul; 76(1):16-22. PubMed ID: 32367746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
    Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD
    N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19 and hypertension.
    Kulkarni S; Jenner BL; Wilkinson I
    J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320927851. PubMed ID: 32431227
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
    Diaz JH
    J Travel Med; 2020 May; 27(3):. PubMed ID: 32186711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
    Cheng H; Wang Y; Wang GQ
    J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs.
    Ciulla MM
    Hypertens Res; 2020 Sep; 43(9):985-986. PubMed ID: 32523133
    [No Abstract]   [Full Text] [Related]  

  • 18. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
    Kurdi A; Abutheraa N; Akil L; Godman B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.
    Wysocki J; Lores E; Ye M; Soler MJ; Batlle D
    J Am Soc Nephrol; 2020 Sep; 31(9):1941-1943. PubMed ID: 32669323
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
    Buckley LF; Cheng JWM; Desai A
    J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.